Global Nucleic Acid and Oligonucleotide Drugs Market Outlook , 2030
The Global Nucleic Acid and Oligonucleotide Drug Market predicts a growth rate exceeding 3.9%, driven by advancements in genetic drug development and rising demand for targeted the
- Bonafide Trust
- 03-07-2024
- Pages : 134
- Figures : 80
- Tables : 145
- Region : Global
- Category : Lifescience & Healthcare
- Pharmaceutical
The global nucleic acid and oligonucleotide drug market is a rapidly expanding section of the pharmaceutical business, distinguished by a focus on cutting-edge medicines that harness the medicinal potential of nucleic acids and oligonucleotides. These medications use nucleic acids such as DNA, RNA, and its derivatives to treat a variety of hereditary, infectious, and chronic disorders. The market is expanding rapidly because to advances in molecular biology, the increased prevalence of genetic disorders, and the growing need for precision medicine. Cancer, cardiovascular disease, genetic disorders, and infectious diseases are all important treatment topics. Oncology remains the largest market, owing to the high prevalence of cancer and the ability of nucleic acid-based medicines to selectively target cancer cells. The first big breakthrough occurred in 1998, when Fomivirsen, an antisense oligonucleotide medication, was approved for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Following this, significant advances were made in the early 2010s with the approval of Kynamro (mipomersen) for homozygous familial hypercholesterolaemia and Spinraza (nusinersen) for spinal muscular atrophy, both of which were critical milestones in the area. Recent years have seen significant expansion with the introduction of mRNA vaccines, such as the Pfizer-BioNTech and Moderna COVID-19 vaccines, demonstrating the potential of mRNA technology in swiftly developing and delivering successful treatments.
According to the research report "Global Nucleic Acid and Oligonucleotide Drug Market Overview, 2030 " published by Bonafide Research, the Global Nucleic Acid and Oligonucleotide Drug market is anticipated to grow at more than 3.9% CAGR from 2024 to 2030. Collaborations among biotechnology businesses, pharmaceutical corporations, and academic institutions are critical for developing nucleic acid and oligonucleotide drug development. Strategic collaborations frequently include combined R&D initiatives, co-marketing agreements, and license agreements. Promotional methods in this sector emphasise the novel character of nucleic acid-based medicines, their ability to meet unmet medical needs, and their role in promoting personalised medicine. Companies employ scientific conferences, medical journals, and digital channels to promote their research discoveries, clinical trial outcomes, and treatment developments. Moderna has worked with Merck to create and commercialise mRNA-based vaccines for infectious illnesses and cancer. BioNTech collaborated with Pfizer to develop mRNA vaccines, notably the COVID-19 vaccine, which was a huge commercial and clinical success. Moderna, which is well-known for its pioneering work in mRNA technology and the development of the COVID-19 vaccine, is now looking into mRNA-based therapeutics for additional infectious diseases and cancer. BioNTech, a leader in mRNA technology, has achieved tremendous progress with its COVID-19 vaccine and is expanding its portfolio to include other mRNA-based treatments and personalised cancer vaccines. Sarepta, which is well-known for gene therapy and exon-skipping methods, is working on treatments for genetic illnesses like Duchenne muscular dystrophy.
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
Technological Advancements in Molecular Biology: Breakthroughs in gene-editing technologies, such as CRISPR/Cas9, are revolutionising the treatment of hereditary illnesses by permitting precise DNA sequence changes. The introduction of RNAi techniques, such as short interfering RNA (siRNA), has permitted targeted gene silencing, opening up new therapeutic possibilities for a variety of disorders.
Rising Prevalence of Genetic Disorders: The prevalence of rare genetic illnesses such as Duchenne muscular dystrophy and cystic fibrosis is increasing, fuelling demand for targeted gene therapies and oligonucleotide-based treatments.
Market Challenges
High creation expenses: The creation of nucleic acid and oligonucleotide pharmaceuticals incurs significant research, development, and manufacturing expenses, which can be a barrier to entry for smaller enterprises.
Complex Regulatory Environment: The regulatory licensing procedure for nucleic acid and oligonucleotide medicines is intricate and severe, necessitating significant clinical trials and safety reviews.
Delivery and Stability Issues: Creating effective delivery vehicles for nucleic acid-based medications, such as lipid nanoparticles for mRNA, remains a difficulty, affecting the efficacy and safety of these treatments.
Market Trends
Expansion of mRNA Technology: The success of mRNA vaccines has led to new applications in cancer immunotherapy and other infectious illnesses. Companies are looking on mRNA-based therapies for a variety of illnesses, including rare genetic abnormalities.
Emergence of Gene Editing Therapies: The development of gene-editing therapeutics utilising CRISPR technology is moving forward, with clinical studies looking into treatments for genetic illnesses such as sickle cell anaemia and beta-thalassemia.
Expedited Pathways: Regulatory authorities are providing expedited approval pathways for potential nucleic acid-based medicines, such as breakthrough therapy and orphan drug designations, allowing for faster market access.
Segmentation Analysis
Based on the report, the type is segmented into into Antisense Oligonucleotides (ASO), siRNA, mRNA.
The mRNA segment is currently leading because to its successful application in COVID-19 vaccines, which demonstrated high efficacy and safety, attracting significant investment and attention. mRNA's rapid development skills, combined with its capacity to cure a wide spectrum of illnesses, contribute to its market supremacy. Furthermore, the adaptability and scalability of mRNA synthesis processes add to its significance when compared to ASOs and siRNA, which, while essential, have fewer uses and face more complex delivery challenges. mRNA treatments, as evidenced by the efficacy of COVID-19 vaccines, use mRNA to instruct cells to produce proteins that can stimulate an immune response or correct disease-causing protein deficiencies. . Antisense Oligonucleotides (ASOs) are designed to bind to specific mRNA regions and influence gene expression by promoting mRNA degradation or hindering translation. This approach is very effective for treating hereditary disorders and certain cancers. Notable examples are Spinraza (nusinersen) for spinal muscular atrophy and Onpattro (patisiran) for hereditary transthyretin-mediated amyloidosis. siRNA works by RNA interference, which induces the breakdown of complementary mRNA, effectively silencing specific genes. siRNA-based treatments target and downregulate genes associated with diseases such as viral infections and cancer.
Based on the report, the application is segmented into Neuromuscular Diseases, hATTR, COVID-19, Other.
The global nucleic acid and oligonucleotide treatments market is divided into therapeutic segments that address a wide range of conditions, including neuromuscular diseases, hereditary transthyretin amyloidosis (hATTR), COVID-19, and others. Spinraza (nusinersen), an antisense oligonucleotide (ASO), is used to treat neuromuscular diseases such spinal muscular atrophy (SMA). These medications work by changing gene expression to compensate for the defective genes that cause muscle degeneration, which is a significant step forward in treating these severe disorders. Onpattro (patisiran) and Tegsedi (inotersen) are RNA-based drugs that effectively treat hereditary transthyretin amyloidosis (hATTR), a rare and progressive disease caused by the accumulation of misfolded transthyretin protein. These treatments use RNA interference (RNAi) to reduce mutant protein production. The COVID-19 pandemic has highlighted the significance of nucleic acid therapies, such as mRNA vaccines developed by Pfizer-BioNTech and Moderna. These vaccines use mRNA to direct cells to produce a protein that causes an immune response to the SARS-CoV-2 virus. Because of their rapid development and high efficacy, mRNA vaccines have emerged as market leaders.
Regional Analysis
The Asia-Pacific region is leading the global market for nucleic acid and oligonucleotide drugs due to a combination of robust investment in biotechnology and significant advancements in research.
Asia-Pacific countries, particularly China, Japan, and South Korea, have emerged as major players in the nucleic acid treatments market. These countries have increased their investment in biotechnology and life sciences, aided by government initiatives and financial programs aimed at encouraging research and development in this field. China, for example, has launched national initiatives like "Made in China 2025" to encourage the development of biopharmaceuticals and cutting-edge technology, such as nucleic acid-based therapies. Innovation and Research: The region has pioneered numerous groundbreaking advances in nucleic acid medicines. In China, breakthroughs in CRISPR/Cas9 gene editing and RNAi technologies have resulted in the development of new therapy options.
Key Development
• In March 2024, Ionis Pharmaceuticals and Biogen Announce Positive Results for ALS Therapy: Ionis Pharmaceuticals and Biogen have announced positive phase 3 clinical trial results for their antisense oligonucleotide therapy for amyotrophic lateral sclerosis (ALS), paving the way for potential new neurodegenerative disease treatments.
• In February 2024, Sarepta Therapeutics Receives EU Approval for DMD Gene Therapy: The European Medicines Agency (EMA) approved Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy (DMD), highlighting the growing acceptance and regulatory support for nucleic acid-based treatments.
• In January 2024, Arcturus Therapeutics Commences Phase 2 Clinical studies for mRNA-Based Liver Disease Treatment: Arcturus Therapeutics announced the start of Phase 2 clinical studies for their mRNA-based treatment for liver illnesses, demonstrating the growing possibilities of mRNA technology.
Table of Contents
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Nucleic Acid and Oligonucleotide Drugs Market Size 2019-2030
- 2.1.2 Nucleic Acid and Oligonucleotide Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030)
- 2.1.3 World Current & Future Analysis for Nucleic Acid and Oligonucleotide Drugs by Country/Region, 2019, 2023 & 2030
- 2.2 Nucleic Acid and Oligonucleotide Drugs Segment by Type
- 2.2.1 Antisense Oligonucleotides (ASO)
- 2.2.2 siRNA
- 2.2.3 mRNA
- 2.3 Nucleic Acid and Oligonucleotide Drugs Market Size by Type
- 2.3.1 Nucleic Acid and Oligonucleotide Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
- 2.3.2 Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2024)
- 2.4 Nucleic Acid and Oligonucleotide Drugs Segment by Application
- 2.4.1 Neuromuscular Diseases
- 2.4.2 hATTR
- 2.4.3 COVID-19
- 2.4.4 Other
- 2.5 Nucleic Acid and Oligonucleotide Drugs Market Size by Application
- 2.5.1 Nucleic Acid and Oligonucleotide Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
- 2.5.2 Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application (2019-2024)
- 3 Nucleic Acid and Oligonucleotide Drugs Market Size by Player
- 3.1 Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Player
- 3.1.1 Global Nucleic Acid and Oligonucleotide Drugs Revenue by Player (2019-2024)
- 3.1.2 Global Nucleic Acid and Oligonucleotide Drugs Revenue Market Share by Player (2019-2024)
- 3.2 Global Nucleic Acid and Oligonucleotide Drugs Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
- 4 Nucleic Acid and Oligonucleotide Drugs by Region
- 4.1 Nucleic Acid and Oligonucleotide Drugs Market Size by Region (2019-2024)
- 4.2 Global Nucleic Acid and Oligonucleotide Drugs Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Nucleic Acid and Oligonucleotide Drugs Market Size Growth (2019-2024)
- 4.4 APAC Nucleic Acid and Oligonucleotide Drugs Market Size Growth (2019-2024)
- 4.5 Europe Nucleic Acid and Oligonucleotide Drugs Market Size Growth (2019-2024)
- 4.6 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size Growth (2019-2024)
- 5 Americas
- 5.1 Americas Nucleic Acid and Oligonucleotide Drugs Market Size by Country (2019-2024)
- 5.2 Americas Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024)
- 5.3 Americas Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Nucleic Acid and Oligonucleotide Drugs Market Size by Region (2019-2024)
- 6.2 APAC Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024)
- 6.3 APAC Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 7 Europe
- 7.1 Europe Nucleic Acid and Oligonucleotide Drugs Market Size by Country (2019-2024)
- 7.2 Europe Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024)
- 7.3 Europe Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs by Region (2019-2024)
- 8.2 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024)
- 8.3 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Global Nucleic Acid and Oligonucleotide Drugs Market Forecast
- 10.1 Global Nucleic Acid and Oligonucleotide Drugs Forecast by Region (2025-2030)
- 10.1.1 Global Nucleic Acid and Oligonucleotide Drugs Forecast by Region (2025-2030)
- 10.1.2 Americas Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.1.3 APAC Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.1.4 Europe Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.1.5 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.2 Americas Nucleic Acid and Oligonucleotide Drugs Forecast by Country (2025-2030)
- 10.2.1 United States Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.2.2 Canada Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.2.3 Mexico Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.2.4 Brazil Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.3 APAC Nucleic Acid and Oligonucleotide Drugs Forecast by Region (2025-2030)
- 10.3.1 China Nucleic Acid and Oligonucleotide Drugs Market Forecast
- 10.3.2 Japan Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.3.3 Korea Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.3.4 Southeast Asia Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.3.5 India Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.3.6 Australia Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.4 Europe Nucleic Acid and Oligonucleotide Drugs Forecast by Country (2025-2030)
- 10.4.1 Germany Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.4.2 France Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.4.3 UK Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.4.4 Italy Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.4.5 Russia Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.5 Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Forecast by Region (2025-2030)
- 10.5.1 Egypt Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.5.2 South Africa Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.5.3 Israel Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.5.4 Turkey Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 10.6 Global Nucleic Acid and Oligonucleotide Drugs Forecast by Type (2025-2030)
- 10.7 Global Nucleic Acid and Oligonucleotide Drugs Forecast by Application (2025-2030)
- 10.7.1 GCC Countries Market Nucleic Acid and Oligonucleotide Drugs Forecast
- 11 Key Players Analysis
- 11.1 Sarepta Therapeutics
- 11.1.1 Sarepta Therapeutics Company Information
- 11.1.2 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.1.3 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.1.4 Sarepta Therapeutics Main Business Overview
- 11.1.5 Sarepta Therapeutics Latest Developments
- 11.2 Ionis Pharmaceuticals
- 11.2.1 Ionis Pharmaceuticals Company Information
- 11.2.2 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.2.3 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.2.4 Ionis Pharmaceuticals Main Business Overview
- 11.2.5 Ionis Pharmaceuticals Latest Developments
- 11.3 Alnylam
- 11.3.1 Alnylam Company Information
- 11.3.2 Alnylam Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.3.3 Alnylam Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.3.4 Alnylam Main Business Overview
- 11.3.5 Alnylam Latest Developments
- 11.4 Biogen
- 11.4.1 Biogen Company Information
- 11.4.2 Biogen Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.4.3 Biogen Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.4.4 Biogen Main Business Overview
- 11.4.5 Biogen Latest Developments
- 11.5 Nippon Shinyaku
- 11.5.1 Nippon Shinyaku Company Information
- 11.5.2 Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.5.3 Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.5.4 Nippon Shinyaku Main Business Overview
- 11.5.5 Nippon Shinyaku Latest Developments
- 11.6 Sobi
- 11.6.1 Sobi Company Information
- 11.6.2 Sobi Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.6.3 Sobi Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.6.4 Sobi Main Business Overview
- 11.6.5 Sobi Latest Developments
- 11.7 Novartis
- 11.7.1 Novartis Company Information
- 11.7.2 Novartis Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.7.3 Novartis Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.7.4 Novartis Main Business Overview
- 11.7.5 Novartis Latest Developments
- 11.8 BioNTech
- 11.8.1 BioNTech Company Information
- 11.8.2 BioNTech Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.8.3 BioNTech Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.8.4 BioNTech Main Business Overview
- 11.8.5 BioNTech Latest Developments
- 11.9 Pfizer
- 11.9.1 Pfizer Company Information
- 11.9.2 Pfizer Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.9.3 Pfizer Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.9.4 Pfizer Main Business Overview
- 11.9.5 Pfizer Latest Developments
- 11.10 Moderna Therapeutics
- 11.10.1 Moderna Therapeutics Company Information
- 11.10.2 Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.10.3 Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.10.4 Moderna Therapeutics Main Business Overview
- 11.10.5 Moderna Therapeutics Latest Developments
- 11.11 Jazz Pharmaceuticals
- 11.11.1 Jazz Pharmaceuticals Company Information
- 11.11.2 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.11.3 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.11.4 Jazz Pharmaceuticals Main Business Overview
- 11.11.5 Jazz Pharmaceuticals Latest Developments
- 11.12 CureVac
- 11.12.1 CureVac Company Information
- 11.12.2 CureVac Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.12.3 CureVac Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.12.4 CureVac Main Business Overview
- 11.12.5 CureVac Latest Developments
- 11.13 Regulus Therapeutics
- 11.13.1 Regulus Therapeutics Company Information
- 11.13.2 Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.13.3 Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.13.4 Regulus Therapeutics Main Business Overview
- 11.13.5 Regulus Therapeutics Latest Developments
- 11.14 ProQR
- 11.14.1 ProQR Company Information
- 11.14.2 ProQR Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.14.3 ProQR Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.14.4 ProQR Main Business Overview
- 11.14.5 ProQR Latest Developments
- 11.15 Secarna
- 11.15.1 Secarna Company Information
- 11.15.2 Secarna Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.15.3 Secarna Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.15.4 Secarna Main Business Overview
- 11.15.5 Secarna Latest Developments
- 11.16 MiNA Therapeutics
- 11.16.1 MiNA Therapeutics Company Information
- 11.16.2 MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.16.3 MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.16.4 MiNA Therapeutics Main Business Overview
- 11.16.5 MiNA Therapeutics Latest Developments
- 11.17 Sylentis
- 11.17.1 Sylentis Company Information
- 11.17.2 Sylentis Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.17.3 Sylentis Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.17.4 Sylentis Main Business Overview
- 11.17.5 Sylentis Latest Developments
- 11.18 Arrowhead
- 11.18.1 Arrowhead Company Information
- 11.18.2 Arrowhead Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.18.3 Arrowhead Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.18.4 Arrowhead Main Business Overview
- 11.18.5 Arrowhead Latest Developments
- 11.19 Silence Therapeutics
- 11.19.1 Silence Therapeutics Company Information
- 11.19.2 Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.19.3 Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.19.4 Silence Therapeutics Main Business Overview
- 11.19.5 Silence Therapeutics Latest Developments
- 11.20 Dicerna
- 11.20.1 Dicerna Company Information
- 11.20.2 Dicerna Nucleic Acid and Oligonucleotide Drugs Product Offered
- 11.20.3 Dicerna Nucleic Acid and Oligonucleotide Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.20.4 Dicerna Main Business Overview
- 11.20.5 Dicerna Latest Developments
- 12 Research Findings and Conclusion
List of Tables
Table 1. Nucleic Acid and Oligonucleotide Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Nucleic Acid and Oligonucleotide Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. Nucleic Acid and Oligonucleotide Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 7. Global Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024) & ($ millions)
Table 8. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2024)
Table 9. Nucleic Acid and Oligonucleotide Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 10. Global Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024) & ($ millions)
Table 11. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application (2019-2024)
Table 12. Global Nucleic Acid and Oligonucleotide Drugs Revenue by Player (2019-2024) & ($ millions)
Table 13. Global Nucleic Acid and Oligonucleotide Drugs Revenue Market Share by Player (2019-2024)
Table 14. Nucleic Acid and Oligonucleotide Drugs Key Players Head office and Products Offered
Table 15. Nucleic Acid and Oligonucleotide Drugs Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Nucleic Acid and Oligonucleotide Drugs Market Size by Region (2019-2024) & ($ millions)
Table 19. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Region (2019-2024)
Table 20. Global Nucleic Acid and Oligonucleotide Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 21. Global Nucleic Acid and Oligonucleotide Drugs Revenue Market Share by Country/Region (2019-2024)
Table 22. Americas Nucleic Acid and Oligonucleotide Drugs Market Size by Country (2019-2024) & ($ millions)
Table 23. Americas Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Country (2019-2024)
Table 24. Americas Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024) & ($ millions)
Table 25. Americas Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2024)
Table 26. Americas Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024) & ($ millions)
Table 27. Americas Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application (2019-2024)
Table 28. APAC Nucleic Acid and Oligonucleotide Drugs Market Size by Region (2019-2024) & ($ millions)
Table 29. APAC Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Region (2019-2024)
Table 30. APAC Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024) & ($ millions)
Table 31. APAC Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024) & ($ millions)
Table 32. Europe Nucleic Acid and Oligonucleotide Drugs Market Size by Country (2019-2024) & ($ millions)
Table 33. Europe Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Country (2019-2024)
Table 34. Europe Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024) & ($ millions)
Table 35. Europe Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024) & ($ millions)
Table 36. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size by Region (2019-2024) & ($ millions)
Table 37. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024) & ($ millions)
Table 38. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Nucleic Acid and Oligonucleotide Drugs
Table 40. Key Market Challenges & Risks of Nucleic Acid and Oligonucleotide Drugs
Table 41. Key Industry Trends of Nucleic Acid and Oligonucleotide Drugs
Table 42. Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Region (2025-2030) & ($ millions)
Table 43. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share Forecast by Region (2025-2030)
Table 44. Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Type (2025-2030) & ($ millions)
Table 45. Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Application (2025-2030) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 47. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 48. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 53. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 57. Alnylam Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 58. Alnylam Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 62. Biogen Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 63. Biogen Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 67. Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 68. Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 72. Sobi Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 73. Sobi Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 77. Novartis Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 78. Novartis Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 82. BioNTech Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 83. BioNTech Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 87. Pfizer Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 88. Pfizer Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 92. Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 93. Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 98. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 102. CureVac Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 103. CureVac Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 107. Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 108. Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 112. ProQR Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 113. ProQR Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 117. Secarna Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 118. Secarna Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 122. MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 123. MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 127. Sylentis Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 128. Sylentis Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 132. Arrowhead Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 133. Arrowhead Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 137. Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 138. Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 142. Dicerna Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 143. Dicerna Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
Table 1. Nucleic Acid and Oligonucleotide Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Nucleic Acid and Oligonucleotide Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. Nucleic Acid and Oligonucleotide Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 7. Global Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024) & ($ millions)
Table 8. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2024)
Table 9. Nucleic Acid and Oligonucleotide Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 10. Global Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024) & ($ millions)
Table 11. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application (2019-2024)
Table 12. Global Nucleic Acid and Oligonucleotide Drugs Revenue by Player (2019-2024) & ($ millions)
Table 13. Global Nucleic Acid and Oligonucleotide Drugs Revenue Market Share by Player (2019-2024)
Table 14. Nucleic Acid and Oligonucleotide Drugs Key Players Head office and Products Offered
Table 15. Nucleic Acid and Oligonucleotide Drugs Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Nucleic Acid and Oligonucleotide Drugs Market Size by Region (2019-2024) & ($ millions)
Table 19. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Region (2019-2024)
Table 20. Global Nucleic Acid and Oligonucleotide Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 21. Global Nucleic Acid and Oligonucleotide Drugs Revenue Market Share by Country/Region (2019-2024)
Table 22. Americas Nucleic Acid and Oligonucleotide Drugs Market Size by Country (2019-2024) & ($ millions)
Table 23. Americas Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Country (2019-2024)
Table 24. Americas Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024) & ($ millions)
Table 25. Americas Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2024)
Table 26. Americas Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024) & ($ millions)
Table 27. Americas Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application (2019-2024)
Table 28. APAC Nucleic Acid and Oligonucleotide Drugs Market Size by Region (2019-2024) & ($ millions)
Table 29. APAC Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Region (2019-2024)
Table 30. APAC Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024) & ($ millions)
Table 31. APAC Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024) & ($ millions)
Table 32. Europe Nucleic Acid and Oligonucleotide Drugs Market Size by Country (2019-2024) & ($ millions)
Table 33. Europe Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Country (2019-2024)
Table 34. Europe Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024) & ($ millions)
Table 35. Europe Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024) & ($ millions)
Table 36. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size by Region (2019-2024) & ($ millions)
Table 37. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size by Type (2019-2024) & ($ millions)
Table 38. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size by Application (2019-2024) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Nucleic Acid and Oligonucleotide Drugs
Table 40. Key Market Challenges & Risks of Nucleic Acid and Oligonucleotide Drugs
Table 41. Key Industry Trends of Nucleic Acid and Oligonucleotide Drugs
Table 42. Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Region (2025-2030) & ($ millions)
Table 43. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share Forecast by Region (2025-2030)
Table 44. Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Type (2025-2030) & ($ millions)
Table 45. Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Application (2025-2030) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 47. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 48. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 53. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 57. Alnylam Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 58. Alnylam Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 62. Biogen Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 63. Biogen Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 67. Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 68. Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 72. Sobi Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 73. Sobi Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 77. Novartis Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 78. Novartis Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 82. BioNTech Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 83. BioNTech Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 87. Pfizer Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 88. Pfizer Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 92. Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 93. Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 98. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 102. CureVac Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 103. CureVac Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 107. Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 108. Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 112. ProQR Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 113. ProQR Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 117. Secarna Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 118. Secarna Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 122. MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 123. MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 127. Sylentis Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 128. Sylentis Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 132. Arrowhead Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 133. Arrowhead Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 137. Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 138. Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, Nucleic Acid and Oligonucleotide Drugs Area Served and Its Competitors
Table 142. Dicerna Nucleic Acid and Oligonucleotide Drugs Product Offered
Table 143. Dicerna Nucleic Acid and Oligonucleotide Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
List of Figures
Figure 1. Nucleic Acid and Oligonucleotide Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Nucleic Acid and Oligonucleotide Drugs Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Nucleic Acid and Oligonucleotide Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Country/Region (2023)
Figure 8. Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type in 2023
Figure 10. Nucleic Acid and Oligonucleotide Drugs in Neuromuscular Diseases
Figure 11. Global Nucleic Acid and Oligonucleotide Drugs Market: Neuromuscular Diseases (2019-2024) & ($ millions)
Figure 12. Nucleic Acid and Oligonucleotide Drugs in hATTR
Figure 13. Global Nucleic Acid and Oligonucleotide Drugs Market: hATTR (2019-2024) & ($ millions)
Figure 14. Nucleic Acid and Oligonucleotide Drugs in COVID-19
Figure 15. Global Nucleic Acid and Oligonucleotide Drugs Market: COVID-19 (2019-2024) & ($ millions)
Figure 16. Nucleic Acid and Oligonucleotide Drugs in Other
Figure 17. Global Nucleic Acid and Oligonucleotide Drugs Market: Other (2019-2024) & ($ millions)
Figure 18. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application in 2023
Figure 19. Global Nucleic Acid and Oligonucleotide Drugs Revenue Market Share by Player in 2023
Figure 20. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Region (2019-2024)
Figure 21. Americas Nucleic Acid and Oligonucleotide Drugs Market Size 2019-2024 ($ millions)
Figure 22. APAC Nucleic Acid and Oligonucleotide Drugs Market Size 2019-2024 ($ millions)
Figure 23. Europe Nucleic Acid and Oligonucleotide Drugs Market Size 2019-2024 ($ millions)
Figure 24. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size 2019-2024 ($ millions)
Figure 25. Americas Nucleic Acid and Oligonucleotide Drugs Value Market Share by Country in 2023
Figure 26. United States Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 27. Canada Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 28. Mexico Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 29. Brazil Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 30. APAC Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Region in 2023
Figure 31. APAC Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2024)
Figure 32. APAC Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application (2019-2024)
Figure 33. China Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 34. Japan Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 35. South Korea Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 36. Southeast Asia Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 37. India Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 38. Australia Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 39. Europe Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Country in 2023
Figure 40. Europe Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2024)
Figure 41. Europe Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application (2019-2024)
Figure 42. Germany Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 43. France Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 44. UK Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 45. Italy Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 46. Russia Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 47. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 51. South Africa Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 52. Israel Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 53. Turkey Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 54. GCC Countries Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 55. Americas Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 56. APAC Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 57. Europe Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 58. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 59. United States Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 60. Canada Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 61. Mexico Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 62. Brazil Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 63. China Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 64. Japan Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 65. Korea Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 66. Southeast Asia Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 67. India Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 68. Australia Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 69. Germany Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 70. France Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 71. UK Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 72. Italy Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 73. Russia Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 74. Egypt Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 75. South Africa Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 76. Israel Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 77. Turkey Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 78. GCC Countries Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 79. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share Forecast by Type (2025-2030)
Figure 80. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share Forecast by Application (2025-2030)
"
Figure 1. Nucleic Acid and Oligonucleotide Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Nucleic Acid and Oligonucleotide Drugs Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Nucleic Acid and Oligonucleotide Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Country/Region (2023)
Figure 8. Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type in 2023
Figure 10. Nucleic Acid and Oligonucleotide Drugs in Neuromuscular Diseases
Figure 11. Global Nucleic Acid and Oligonucleotide Drugs Market: Neuromuscular Diseases (2019-2024) & ($ millions)
Figure 12. Nucleic Acid and Oligonucleotide Drugs in hATTR
Figure 13. Global Nucleic Acid and Oligonucleotide Drugs Market: hATTR (2019-2024) & ($ millions)
Figure 14. Nucleic Acid and Oligonucleotide Drugs in COVID-19
Figure 15. Global Nucleic Acid and Oligonucleotide Drugs Market: COVID-19 (2019-2024) & ($ millions)
Figure 16. Nucleic Acid and Oligonucleotide Drugs in Other
Figure 17. Global Nucleic Acid and Oligonucleotide Drugs Market: Other (2019-2024) & ($ millions)
Figure 18. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application in 2023
Figure 19. Global Nucleic Acid and Oligonucleotide Drugs Revenue Market Share by Player in 2023
Figure 20. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Region (2019-2024)
Figure 21. Americas Nucleic Acid and Oligonucleotide Drugs Market Size 2019-2024 ($ millions)
Figure 22. APAC Nucleic Acid and Oligonucleotide Drugs Market Size 2019-2024 ($ millions)
Figure 23. Europe Nucleic Acid and Oligonucleotide Drugs Market Size 2019-2024 ($ millions)
Figure 24. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size 2019-2024 ($ millions)
Figure 25. Americas Nucleic Acid and Oligonucleotide Drugs Value Market Share by Country in 2023
Figure 26. United States Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 27. Canada Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 28. Mexico Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 29. Brazil Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 30. APAC Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Region in 2023
Figure 31. APAC Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2024)
Figure 32. APAC Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application (2019-2024)
Figure 33. China Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 34. Japan Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 35. South Korea Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 36. Southeast Asia Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 37. India Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 38. Australia Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 39. Europe Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Country in 2023
Figure 40. Europe Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2024)
Figure 41. Europe Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application (2019-2024)
Figure 42. Germany Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 43. France Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 44. UK Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 45. Italy Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 46. Russia Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 47. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 51. South Africa Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 52. Israel Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 53. Turkey Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 54. GCC Countries Nucleic Acid and Oligonucleotide Drugs Market Size Growth 2019-2024 ($ millions)
Figure 55. Americas Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 56. APAC Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 57. Europe Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 58. Middle East & Africa Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 59. United States Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 60. Canada Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 61. Mexico Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 62. Brazil Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 63. China Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 64. Japan Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 65. Korea Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 66. Southeast Asia Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 67. India Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 68. Australia Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 69. Germany Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 70. France Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 71. UK Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 72. Italy Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 73. Russia Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 74. Egypt Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 75. South Africa Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 76. Israel Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 77. Turkey Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 78. GCC Countries Nucleic Acid and Oligonucleotide Drugs Market Size 2025-2030 ($ millions)
Figure 79. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share Forecast by Type (2025-2030)
Figure 80. Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share Forecast by Application (2025-2030)
"
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (09 May, 2026)
- Notify To Team (09 May, 2026)
- Report updation (10 May, 2026)
- Report Quality Check (10 May, 2026)
- Report Dispatch (11 May, 2026)
- Hard Copy
Recently Viewed Products
Global Nucleic Acid and Oligonucleotide Drugs Market Outlook , 2030
We are friendly and approachable, give us a call.